A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
← catalyst calendarNCT07412691 · readout in 719 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
98estimated
Sites
11
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-19 | actual | When the study began enrolling |
| Primary completion | 2028-08-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-08 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Skin Diseases
Interventions
- Biological: BG-A3004
- Biological: Placebo
Primary outcome
what the primary-completion date above is the date OFPart A (SAD) and Part B (MAD): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured up to 24 weeks for Part A and 36 weeks for Part B
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed